Results 341 to 350 of about 4,204,651 (354)

Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial

Lancet, The, 2014
Marcia S Brose, Barbara Jarząb, Rossella Elisei   +2 more
exaly  

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort

Lancet, The, 2010
Luca Gianni, Vladimir Semiglazov, Alexey Manikhas   +2 more
exaly  

Personalized care for patients with EGFR‐mutant nonsmall cell lung cancer: Navigating early to advanced disease management

Ca-A Cancer Journal for Clinicians
Maxime Borgeaud, Jair Bar, Stephanie Saw
exaly  

First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study.

The Lancet Oncology, 2017
A. Balar, D. Castellano, P. O’Donnell, P. Grivas, J. Vuky, T. Powles, E. Plimack, N. Hahn, R. de Wit, Lei Pang, M. Savage, R. Perini, S. Keefe, D. Bajorin, J. Bellmunt   +14 more
semanticscholar   +1 more source

Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial

Lancet, The, 2009
Anders Widmark, Per Fransson, Morten Hoyer   +2 more
exaly  

Management of locally advanced breast cancer—perspectives and future directions

Nature Reviews Clinical Oncology, 2015
Konstantinos Tryfonidis, Elżbieta Senkus   +1 more
exaly  

Recent Advances in Local Anesthetics

Medical Clinics of North America, 1958
openaire   +2 more sources

Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial

Lancet, The, 2002
Laurence Collette, Padraig R Warde, Jacques Bernier   +2 more
exaly  

Local Advancement Flap

2018
openaire   +1 more source

Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial

Lancet, The
Stephan Polterauer, Linda R Duska, Domenica Lorusso   +2 more
exaly